Medical - Devices
Compare Stocks
2 / 10Stock Comparison
INSP vs IRTC
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Devices
INSP vs IRTC — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Medical - Devices | Medical - Devices |
| Market Cap | $1.32B | $3.87B |
| Revenue (TTM) | $915M | $788M |
| Net Income (TTM) | $131M | $-28M |
| Gross Margin | 85.8% | 71.0% |
| Operating Margin | 5.6% | -3.3% |
| Forward P/E | 24.5x | — |
| Total Debt | $32M | $731M |
| Cash & Equiv. | $105M | $236M |
INSP vs IRTC — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Inspire Medical Sys… (INSP) | 100 | 56.0 | -44.0% |
| iRhythm Technologie… (IRTC) | 100 | 94.7 | -5.3% |
Price return only. Dividends and distributions are not included.
Quick Verdict: INSP vs IRTC
Each card shows where this stock fits in a portfolio — not just who wins on paper.
INSP has the current edge in this matchup, primarily because of its strength in growth exposure and sleep-well-at-night.
- Rev growth 13.6%, EPS growth 179.4%, 3Y rev CAGR 30.8%
- Lower volatility, beta 1.27, Low D/E 4.1%, current ratio 6.08x
- Better valuation composite
IRTC is the clearest fit if your priority is income & stability and long-term compounding.
- beta 0.93
- 351.8% 10Y total return vs INSP's 82.9%
- Beta 0.93, current ratio 4.63x
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 26.2% revenue growth vs INSP's 13.6% | |
| Value | Better valuation composite | |
| Quality / Margins | 14.3% margin vs IRTC's -3.5% | |
| Stability / Safety | Beta 0.93 vs INSP's 1.27 | |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | -12.9% vs INSP's -71.8% | |
| Efficiency (ROA) | 15.2% ROA vs IRTC's -2.8%, ROIC 6.0% vs -5.2% |
INSP vs IRTC — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
INSP vs IRTC — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
INSP leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
INSP and IRTC operate at a comparable scale, with $915M and $788M in trailing revenue. INSP is the more profitable business, keeping 14.3% of every revenue dollar as net income compared to IRTC's -3.5%. On growth, IRTC holds the edge at +25.7% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $915M | $788M |
| EBITDAEarnings before interest/tax | $62M | -$6M |
| Net IncomeAfter-tax profit | $131M | -$28M |
| Free Cash FlowCash after capex | $97M | $19M |
| Gross MarginGross profit ÷ Revenue | +85.8% | +71.0% |
| Operating MarginEBIT ÷ Revenue | +5.6% | -3.3% |
| Net MarginNet income ÷ Revenue | +14.3% | -3.5% |
| FCF MarginFCF ÷ Revenue | +10.6% | +2.4% |
| Rev. Growth (YoY)Latest quarter vs prior year | +1.6% | +25.7% |
| EPS Growth (YoY)Latest quarter vs prior year | -5.0% | +55.7% |
Valuation Metrics
INSP leads this category, winning 3 of 4 comparable metrics.
Valuation Metrics
| Metric | ||
|---|---|---|
| Market CapShares × price | $1.3B | $3.9B |
| Enterprise ValueMkt cap + debt − cash | $1.2B | $4.4B |
| Trailing P/EPrice ÷ TTM EPS | 9.35x | -84.68x |
| Forward P/EPrice ÷ next-FY EPS est. | 24.53x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | 19.17x | — |
| Price / SalesMarket cap ÷ Revenue | 1.44x | 5.18x |
| Price / BookPrice ÷ Book value/share | 1.74x | 24.66x |
| Price / FCFMarket cap ÷ FCF | 16.78x | 112.01x |
Profitability & Efficiency
INSP leads this category, winning 9 of 9 comparable metrics.
Profitability & Efficiency
INSP delivers a 18.0% return on equity — every $100 of shareholder capital generates $18 in annual profit, vs $-21 for IRTC. INSP carries lower financial leverage with a 0.04x debt-to-equity ratio, signaling a more conservative balance sheet compared to IRTC's 4.79x. On the Piotroski fundamental quality scale (0–9), INSP scores 7/9 vs IRTC's 6/9, reflecting strong financial health.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | +18.0% | -20.6% |
| ROA (TTM)Return on assets | +15.2% | -2.8% |
| ROICReturn on invested capital | +6.0% | -5.2% |
| ROCEReturn on capital employed | +6.7% | -4.4% |
| Piotroski ScoreFundamental quality 0–9 | 7 | 6 |
| Debt / EquityFinancial leverage | 0.04x | 4.79x |
| Net DebtTotal debt minus cash | -$73M | $495M |
| Cash & Equiv.Liquid assets | $105M | $236M |
| Total DebtShort + long-term debt | $32M | $731M |
| Interest CoverageEBIT ÷ Interest expense | 418.58x | -1.48x |
Total Returns (Dividends Reinvested)
IRTC leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in IRTC five years ago would be worth $15,710 today (with dividends reinvested), compared to $2,385 for INSP. Over the past 12 months, IRTC leads with a -12.9% total return vs INSP's -71.8%. The 3-year compound annual growth rate (CAGR) favors IRTC at -2.6% vs INSP's -45.5% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | -50.5% | -32.8% |
| 1-Year ReturnPast 12 months | -71.8% | -12.9% |
| 3-Year ReturnCumulative with dividends | -83.8% | -7.7% |
| 5-Year ReturnCumulative with dividends | -76.1% | +57.1% |
| 10-Year ReturnCumulative with dividends | +82.9% | +351.8% |
| CAGR (3Y)Annualised 3-year return | -45.5% | -2.6% |
Risk & Volatility
IRTC leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
IRTC is the less volatile stock with a 0.93 beta — it tends to amplify market swings less than INSP's 1.27 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. IRTC currently trades 55.5% from its 52-week high vs INSP's 28.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.27x | 0.93x |
| 52-Week HighHighest price in past year | $163.35 | $212.00 |
| 52-Week LowLowest price in past year | $44.41 | $112.31 |
| % of 52W HighCurrent price vs 52-week peak | +28.0% | +55.5% |
| RSI (14)Momentum oscillator 0–100 | 35.0 | 44.6 |
| Avg Volume (50D)Average daily shares traded | 1.0M | 521K |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates INSP as "Hold" and IRTC as "Buy". Consensus price targets imply 99.8% upside for INSP (target: $91) vs 64.5% for IRTC (target: $194).
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Buy |
| Price TargetConsensus 12-month target | $91.33 | $193.67 |
| # AnalystsCovering analysts | 27 | 19 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +13.3% | 0.0% |
INSP leads in 3 of 6 categories (Income & Cash Flow, Valuation Metrics). IRTC leads in 2 (Total Returns, Risk & Volatility).
INSP vs IRTC: Frequently Asked Questions
9 questions · data-driven answers · updated daily
01Is INSP or IRTC a better buy right now?
For growth investors, iRhythm Technologies, Inc.
(IRTC) is the stronger pick with 26. 2% revenue growth year-over-year, versus 13. 6% for Inspire Medical Systems, Inc. (INSP). Inspire Medical Systems, Inc. (INSP) offers the better valuation at 9. 3x trailing P/E (24. 5x forward), making it the more compelling value choice. Analysts rate iRhythm Technologies, Inc. (IRTC) a "Buy" — based on 19 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — INSP or IRTC?
Over the past 5 years, iRhythm Technologies, Inc.
(IRTC) delivered a total return of +57. 1%, compared to -76. 1% for Inspire Medical Systems, Inc. (INSP). Over 10 years, the gap is even starker: IRTC returned +351. 8% versus INSP's +82. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — INSP or IRTC?
By beta (market sensitivity over 5 years), iRhythm Technologies, Inc.
(IRTC) is the lower-risk stock at 0. 93β versus Inspire Medical Systems, Inc. 's 1. 27β — meaning INSP is approximately 36% more volatile than IRTC relative to the S&P 500. On balance sheet safety, Inspire Medical Systems, Inc. (INSP) carries a lower debt/equity ratio of 4% versus 5% for iRhythm Technologies, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — INSP or IRTC?
By revenue growth (latest reported year), iRhythm Technologies, Inc.
(IRTC) is pulling ahead at 26. 2% versus 13. 6% for Inspire Medical Systems, Inc. (INSP). On earnings-per-share growth, the picture is similar: Inspire Medical Systems, Inc. grew EPS 179. 4% year-over-year, compared to 61. 7% for iRhythm Technologies, Inc.. Over a 3-year CAGR, INSP leads at 30. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — INSP or IRTC?
Inspire Medical Systems, Inc.
(INSP) is the more profitable company, earning 15. 9% net margin versus -6. 0% for iRhythm Technologies, Inc. — meaning it keeps 15. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: INSP leads at 5. 6% versus -4. 9% for IRTC. At the gross margin level — before operating expenses — INSP leads at 85. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is INSP or IRTC more undervalued right now?
Analyst consensus price targets imply the most upside for INSP: 99.
8% to $91. 33.
07Which pays a better dividend — INSP or IRTC?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
08Is INSP or IRTC better for a retirement portfolio?
For long-horizon retirement investors, iRhythm Technologies, Inc.
(IRTC) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 93), +351. 8% 10Y return). Both have compounded well over 10 years (IRTC: +351. 8%, INSP: +82. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between INSP and IRTC?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: INSP is a small-cap deep-value stock; IRTC is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.